Our Experienced Management Team

10+ years Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA
Expert in clinical development and regulatory compliance and responsible for the success of multiple NDAs, rheumatologist and board-certified internist
Successful development and approval of droxidop

10+ years Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA
Expert in clinical development and regulatory compliance and responsible for the success of multiple NDAs, rheumatologist and board-certified internist
Successful development and approval of droxidopa (Northera) at Chelsea Therapeutics-sold to Lundbeck for $650M in 2014

Expert in virtual start-ups and both national and multi-national outsourcing
Over twenty years in small and startup pharma in executive positions and played an integral part in the success of three NDA filings
Co-Founder Corus Pharma, sold to Gilead $365M in 2006

Former founding scientist and Senior Director of Chemistry, Paratek Pharmaceuticals, Inc., Boston
Inventor of NuzyraTM and SeysaraTM- FDA Approved 2018
Holds 40 U.S. and foreign patents in antibiotics and human therapeutics
BARDA purchased $330M of NuzyraTM for strategic national stockpile against Anthrax